DK2331538T3 - Krystallinske former af en 2-thiazolyl-4-quinolinyl-oxy-derivat, en potent HCV-inhibitor - Google Patents
Krystallinske former af en 2-thiazolyl-4-quinolinyl-oxy-derivat, en potent HCV-inhibitorInfo
- Publication number
- DK2331538T3 DK2331538T3 DK09792493.0T DK09792493T DK2331538T3 DK 2331538 T3 DK2331538 T3 DK 2331538T3 DK 09792493 T DK09792493 T DK 09792493T DK 2331538 T3 DK2331538 T3 DK 2331538T3
- Authority
- DK
- Denmark
- Prior art keywords
- quinolinyl
- thiazolyl
- crystalline forms
- hcv inhibitor
- oxy derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9729108P | 2008-09-16 | 2008-09-16 | |
| US15082609P | 2009-03-09 | 2009-03-09 | |
| PCT/US2009/056772 WO2010033444A1 (en) | 2008-09-16 | 2009-09-14 | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2331538T3 true DK2331538T3 (da) | 2014-06-02 |
Family
ID=41268627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09792493.0T DK2331538T3 (da) | 2008-09-16 | 2009-09-14 | Krystallinske former af en 2-thiazolyl-4-quinolinyl-oxy-derivat, en potent HCV-inhibitor |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8232293B2 (da) |
| EP (2) | EP2331538B1 (da) |
| JP (2) | JP5520301B2 (da) |
| KR (1) | KR101653550B1 (da) |
| CN (1) | CN102159571B (da) |
| AR (1) | AR073298A1 (da) |
| AU (1) | AU2009293494B2 (da) |
| BR (1) | BRPI0918513A2 (da) |
| CA (1) | CA2737055C (da) |
| CL (1) | CL2011000558A1 (da) |
| CO (1) | CO6351741A2 (da) |
| CY (1) | CY1115253T1 (da) |
| DK (1) | DK2331538T3 (da) |
| EA (1) | EA018603B1 (da) |
| EC (1) | ECSP11010878A (da) |
| ES (1) | ES2474992T3 (da) |
| HK (1) | HK1156624A1 (da) |
| HR (1) | HRP20140666T1 (da) |
| IL (1) | IL210345A (da) |
| MA (1) | MA32633B1 (da) |
| ME (1) | ME01831B (da) |
| MX (1) | MX2011002828A (da) |
| MY (1) | MY153093A (da) |
| NZ (2) | NZ591013A (da) |
| PE (2) | PE20130307A1 (da) |
| PL (1) | PL2331538T3 (da) |
| PT (1) | PT2331538E (da) |
| RS (1) | RS53292B (da) |
| SG (1) | SG189740A1 (da) |
| SI (1) | SI2331538T1 (da) |
| TW (1) | TWI471323B (da) |
| UY (1) | UY32119A (da) |
| WO (1) | WO2010033444A1 (da) |
| ZA (1) | ZA201100096B (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| AU2009293494B2 (en) * | 2008-09-16 | 2014-04-24 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
| BRPI0918653A2 (pt) | 2008-09-17 | 2015-12-01 | Boehringer Ingelheim Int | combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. |
| EP2408382A4 (en) * | 2009-03-13 | 2013-06-19 | Univ Toledo | MINIMALLY INVASIVE COLLABBABLE CAGE |
| WO2010107965A1 (en) * | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
| WO2010129451A1 (en) * | 2009-05-05 | 2010-11-11 | Boehringer Ingelheim International Gmbh | Process for preparing bromo-substituted quinolines |
| ES2464367T3 (es) | 2009-07-07 | 2014-06-02 | Boehringer Ingelheim International Gmbh | Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C |
| WO2011053617A1 (en) | 2009-10-30 | 2011-05-05 | Boehringer Ingelheim International Gmbh | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| BR112013007423A2 (pt) * | 2010-09-30 | 2016-07-12 | Boehringer Ingelheim Int | terapia combinada no que diz respeito ao tratamento da infecção por hcv |
| WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| CA2821340A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| AP2014007760A0 (en) | 2012-01-12 | 2014-07-31 | Boehringer Ingelheim Int | Stabilized pharmaceutical formulations of a potentHCV inhibitor |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| WO2013143581A1 (en) | 2012-03-28 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in specific patient subgenotype sub-population |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| US9732076B2 (en) * | 2013-03-15 | 2017-08-15 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of HCV inhibitor in the amorphous state |
| BR112015021768A2 (pt) | 2013-03-15 | 2016-02-02 | Gilead Sciences Inc | inibidores do vírus da hepatite c |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2022107182A1 (en) * | 2020-11-18 | 2022-05-27 | University Of Petra | A composition of fentanyl and fatty acids, and a method of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1033128T2 (sl) | 1993-09-28 | 2012-02-29 | Scherer Gmbh R P | Izdelava mehke Ĺľelatinaste kapsule |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ，インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
| UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| DE602004010137T2 (de) | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
| WO2005116054A1 (en) * | 2004-05-25 | 2005-12-08 | Boehringer Ingelheim International, Gmbh | Process for preparing acyclic hcv protease inhibitors |
| AU2009293494B2 (en) | 2008-09-16 | 2014-04-24 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
-
2009
- 2009-09-14 AU AU2009293494A patent/AU2009293494B2/en not_active Ceased
- 2009-09-14 DK DK09792493.0T patent/DK2331538T3/da active
- 2009-09-14 NZ NZ591013A patent/NZ591013A/xx not_active IP Right Cessation
- 2009-09-14 CN CN200980136131.XA patent/CN102159571B/zh not_active Expired - Fee Related
- 2009-09-14 EP EP09792493.0A patent/EP2331538B1/en active Active
- 2009-09-14 ES ES09792493.0T patent/ES2474992T3/es active Active
- 2009-09-14 PE PE2012002419A patent/PE20130307A1/es active IP Right Grant
- 2009-09-14 WO PCT/US2009/056772 patent/WO2010033444A1/en active Application Filing
- 2009-09-14 PT PT97924930T patent/PT2331538E/pt unknown
- 2009-09-14 NZ NZ602163A patent/NZ602163A/xx not_active IP Right Cessation
- 2009-09-14 MY MYPI20111140 patent/MY153093A/en unknown
- 2009-09-14 MX MX2011002828A patent/MX2011002828A/es active IP Right Grant
- 2009-09-14 JP JP2011527015A patent/JP5520301B2/ja active Active
- 2009-09-14 PE PE2011000636A patent/PE20110388A1/es not_active Application Discontinuation
- 2009-09-14 SG SG2013024864A patent/SG189740A1/en unknown
- 2009-09-14 EP EP13188665.7A patent/EP2687526A1/en not_active Withdrawn
- 2009-09-14 PL PL09792493T patent/PL2331538T3/pl unknown
- 2009-09-14 RS RS20140230A patent/RS53292B/en unknown
- 2009-09-14 EA EA201100482A patent/EA018603B1/ru not_active IP Right Cessation
- 2009-09-14 ME MEP-2014-43A patent/ME01831B/me unknown
- 2009-09-14 KR KR1020117004209A patent/KR101653550B1/ko active IP Right Grant
- 2009-09-14 BR BRPI0918513A patent/BRPI0918513A2/pt not_active Application Discontinuation
- 2009-09-14 SI SI200930919T patent/SI2331538T1/sl unknown
- 2009-09-14 CA CA2737055A patent/CA2737055C/en not_active Expired - Fee Related
- 2009-09-15 UY UY0001032119A patent/UY32119A/es not_active Application Discontinuation
- 2009-09-15 TW TW98131069A patent/TWI471323B/zh not_active IP Right Cessation
- 2009-09-15 US US12/559,927 patent/US8232293B2/en active Active
- 2009-09-15 AR ARP090103540A patent/AR073298A1/es not_active Application Discontinuation
-
2010
- 2010-12-29 IL IL210345A patent/IL210345A/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00096A patent/ZA201100096B/en unknown
- 2011-03-09 EC EC2011010878A patent/ECSP11010878A/es unknown
- 2011-03-14 MA MA33699A patent/MA32633B1/fr unknown
- 2011-03-16 CO CO11032830A patent/CO6351741A2/es not_active Application Discontinuation
- 2011-03-16 CL CL2011000558A patent/CL2011000558A1/es unknown
- 2011-10-17 HK HK11111031.5A patent/HK1156624A1/xx not_active IP Right Cessation
-
2012
- 2012-07-03 US US13/541,158 patent/US8362035B2/en active Active
-
2013
- 2013-12-09 JP JP2013253812A patent/JP2014062116A/ja not_active Withdrawn
-
2014
- 2014-07-11 CY CY20141100526T patent/CY1115253T1/el unknown
- 2014-07-14 HR HRP20140666AT patent/HRP20140666T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2331538T3 (da) | Krystallinske former af en 2-thiazolyl-4-quinolinyl-oxy-derivat, en potent HCV-inhibitor | |
| DK2262793T3 (da) | Krystallinske former af nilotinib-hci | |
| DK1856050T3 (da) | Krystallinske former af en biphenylforbindelse | |
| DK2149545T3 (da) | Fremgangsmåde til fremstilling af en benzaldehydforbindelse | |
| DK1981875T3 (da) | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase | |
| DK2489662T3 (da) | Mellemprodukter af en ny fremgangsmåde til fremstillingen af 5-benzyliden-2-alkylimino-3-phenylthiazolidin-4-on derivater | |
| DK2508340T3 (da) | Fremgangsmåde til fremstilling af en vandfast cementbaseret genstand | |
| DK1874766T3 (da) | Krystallinsk form af en quinolinon-carboxamid-forbindelse | |
| DK2300465T3 (da) | Imidazopyridinderivater som hæmmere af receptortyrosinkinaser | |
| DK2118090T3 (da) | Fremgangsmåde til fremstilling af et benzimidazolderivat | |
| DK1987159T4 (da) | Fremgangsmåde til sekventering af en polynukleotidtemplate | |
| DK3040333T3 (da) | Krystallinske former af 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluormethylpyridin-2-amin, en pik3-hæmmer | |
| DK2029567T3 (da) | Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater | |
| BRPI0716193A2 (pt) | Replicon derivado de potexvírus | |
| PT2155200T (pt) | Forma cristalina de um derivado de carbamoil-ciclohexano | |
| DK2213654T3 (da) | Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater | |
| DK2155731T3 (da) | 1,3-Dihydroimidazol-2-thion-derivater som inhibitorer af dopamin-beta-hydroxylase | |
| IL221198A0 (en) | Crystalline salts of a potent hcv inhibitor | |
| DK2036818T3 (da) | Fremgangsmåde til fremstilling af en palleløs emballageenhed | |
| DK2049480T3 (da) | 2-arylindolderivater som mPGES-1-hæmmere | |
| EP2373326A4 (en) | CRYSTALLINE FORMS OF GENISTEIN | |
| BRPI0918134A2 (pt) | derivado de prostaglandina i2 | |
| DK2470545T3 (da) | Anhydrate former af et pyridinderivat | |
| DK2170345T3 (da) | Terapeutiske substituerede cyclopentaner til reduktion af intraokulært tryk | |
| DK2430002T3 (da) | FREMGANGSMÅDE TIL FREMSTILLING AF EN FORBINDELSE, DER ER ANVENDELIG SOM EN INHIBITOR AF TAFla |